Julien Robert-Paganin

Dr. Julien Robert-Paganin


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2024 in Nature Cardiovascular Research
Verified
Journal Article
Open access
PDF file
JHJames J. Hartman
James J. Hartman
DHDarren T. Hwee
Darren T. Hwee
JRJulien Robert-Paganin
Julien Robert-Paganin
CCChihyuan Chuang
Chihyuan Chuang
ECEva R. Chin
Eva R. Chin
FMFady I. Malik
Fady I. Malik
Hypertrophic cardiomyopathy (HCM) is an inherited disease of the sarcomere resulting in excessive cardiac contractility. The first-in-class cardiac myosin inhibitor, mavacamten, improves symptoms in obstructive HCM. Here we present aficamten, a selective small-molecule inhibitor of cardiac myosin that diminishes ATPase activity by strongly slowing phosphate release, stabilizing a weak actin-binding state. Binding to an allosteric site on the myosin catalytic domain distinct from mavacamten, aficamten prevents the conformational changes necessary to enter the strongly actin-bound force-generating state. In doing so, aficamten reduces the number of functional myosin heads driving sarcomere shortening. The crystal structure of aficamten bound to cardiac myosin in the pre-powerstroke state provides a basis for understanding its selectivity over smooth and fast skeletal muscle. Furthermore, in cardiac myocytes and in mice bearing the hypertrophic R403Q cardiac myosin mutation, aficamten reduces cardiac contractility. Our findings suggest aficamten holds promise as a therapy for HCM.

31 May 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
AGAlessandro Grinzato
Alessandro Grinzato
DADaniel Auguin
Daniel Auguin
CKCarlos Kikuti
Carlos Kikuti
NNNeha Nandwani
Neha Nandwani
DMDihia Moussaoui
Dihia Moussaoui
JRJulien Robert-Paganin
Julien Robert-Paganin
To save energy and precisely regulate cardiac contractility, cardiac muscle myosin heads are sequestered in an ‘off’ state that can be converted to an ‘on’ state when exertion is increased. The ‘off’ state is equated with a folded-back structure known as the interacting-heads motif (IHM), which is a regulatory feature of all class-2 muscle and non-muscle myosins. We report here the human β-cardiac myosin IHM structure determined by cryo-electron microscopy to 3.6 Å resolution, providing details of all the interfaces stabilizing the ‘off’ state. The structure shows that these interfaces are hot spots of hypertrophic cardiomyopathy mutations that are thought to cause hypercontractility by destabilizing the ‘off’ state. Importantly, the cardiac and smooth muscle myosin IHM structures dramatically differ, providing structural evidence for the divergent physiological regulation of these muscle types. The cardiac IHM structure will facilitate development of clinically useful new molecules that modulate IHM stability.

7 June 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
DADaniel Auguin
Daniel Auguin
JRJulien Robert-Paganin
Julien Robert-Paganin
Stephane RetyStephane Rety
Stephane Rety
CKCarlos Kikuti
Carlos Kikuti
ADAmandine David
Amandine David
Anne HoudusseAnne Houdusse
Anne Houdusse
Inherited cardiomyopathies are common cardiac diseases worldwide, leading in the late stage to heart failure and death. The most promising treatments against these diseases are small molecules directly modulating the force produced by β-cardiac myosin, the molecular motor driving heart contraction. Omecamtiv mecarbil and Mavacamten are two such molecules that completed phase 3 clinical trials, and the inhibitor Mavacamten is now approved by the FDA. In contrast to Mavacamten, Omecamtiv mecarbil acts as an activator of cardiac contractility. Here, we reveal by X-ray crystallography that both drugs target the same pocket and stabilize a pre-stroke structural state, with only few local differences. All-atom molecular dynamics simulations reveal how these molecules produce distinct effects in motor allostery thus impacting force production in opposite way. Altogether, our results provide the framework for rational drug development for the purpose of personalized medicine.

27 August 2024 in The EMBO Journal
Verified
Journal Article
Open access
JSJames A Spudich
James A Spudich
NNNeha Nandwani
Neha Nandwani
JRJulien Robert-Paganin
Julien Robert-Paganin
Anne HoudusseAnne Houdusse
Anne Houdusse
KRKathleen M Ruppel
Kathleen M Ruppel
Human β-cardiac myosin exists in an ON-state where both myosin heads are accessible for interaction with actin, and an OFF-state where the heads are folded back onto their own coiled-coil tail, interacting with each other via an interacting-heads motif (IHM). Hypertrophic cardiomyopathy (HCM) mutations in β-cardiac myosin cause hypercontractility of the heart. Nine years ago, a unifying hypothesis proposed that hypercontractility caused by myosin HCM-associated mutations is primarily due to an increase in the number of ON-state myosin molecules, rather than altered fundamental alterations of functional myosin parameters such as intrinsic motor force, its velocity of movement along actin, or its ATPase turnover rate, all of which impact power output. We here revisit this unifying hypothesis in light of accumulated data measuring all these parameters, and the recent availability of a 3.6 Å-resolution structure of the human β-cardiac myosin IHM. Biochemical measurements show that nearly all myosin HCM mutations examined exhibit more ON-state myosin regardless of where they occur in the myosin head domain, consistent with the unifying hypothesis.

13 October 2020 in eLife
Verified
Journal Article
Open access
DMDihia Moussaoui
Dihia Moussaoui
JRJames P Robblee
James P Robblee
DADaniel Auguin
Daniel Auguin
EKElena B Krementsova
Elena B Krementsova
SHSilvia Haase
Silvia Haase
Anne HoudusseAnne Houdusse
Anne Houdusse
Parasites from the genus Plasmodium are the causative agents of malaria. The mobility, infectivity, and ultimately pathogenesis ofPlasmodium falciparumrely on a macromolecular complex, called the glideosome. At the core of the glideosome is an essential and divergent Myosin A motor (PfMyoA), a first order drug target against malaria. Here, we present the full-length structure of PfMyoA in two states of its motor cycle. We report novel interactions that are essential for motor priming and the mode of recognition of its two light chains (PfELC and MTIP) by two degenerate IQ motifs. Kinetic and motility assays using PfMyoA variants, along with molecular dynamics, demonstrate how specific priming and atypical sequence adaptations tune the motor’s mechano-chemical properties. Supported by evidence for an essential role of the PfELC in malaria pathogenesis, these structures provide a blueprint for the design of future anti-malarials targeting both the glideosome motor and its regulatory elements.

12 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
DMDihia Moussaoui
Dihia Moussaoui
JRJames P. Robblee
James P. Robblee
JRJulien Robert-Paganin
Julien Robert-Paganin
DADaniel Auguin
Daniel Auguin
FFFabio Fisher
Fabio Fisher
Anne HoudusseAnne Houdusse
Anne Houdusse
Malaria results in more than 500,000 deaths per year and the causative Plasmodium parasites continue to develop resistance to all known agents, including different antimalarial combinations. The class XIV myosin motor PfMyoA is part of a core macromolecular complex called the glideosome, essential for Plasmodium parasite mobility and therefore an attractive drug target. Here, we characterize the interaction of a small molecule (KNX-002) with PfMyoA. KNX-002 inhibits PfMyoA ATPase activity in vitro and blocks asexual blood stage growth of merozoites, one of three motile Plasmodium life-cycle stages. Combining biochemical assays and X-ray crystallography, we demonstrate that KNX-002 inhibits PfMyoA using a previously undescribed binding mode, sequestering it in a post-rigor state detached from actin. KNX-002 binding prevents efficient ATP hydrolysis and priming of the lever arm, thus inhibiting motor activity. This small-molecule inhibitor of PfMyoA paves the way for the development of alternative antimalarial treatments.